![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Effect of Renal Function on the Pharmacokinetics of Ombitasvir/Paritaprevir/Ritonavir, Dasabuvir and Ribavirin in Over 2000 Subjects with HCV GT1 Infection
|
|
|
Reported by Jules Levin
AASLD 2015 Nov 13-17 San Francisco
A.R. Polepally1, P. S. Badri1, D. Eckert2, S. Mensing2, R. M. Menon1 1AbbVie Inc., Clinical Pharmacology and Pharmacometrics, North Chicago, IL, USA 2AbbVie Deutschland GmbH & Co.KG, Clinical Pharmacology and Pharmacometrics, Ludwigshafen, Germany
![AASLD1.gif](../images/121615/121615-8/AASLD1.gif)
![AASLD2.gif](../images/121615/121615-8/AASLD2.gif)
![AASLD3.gif](../images/121615/121615-8/AASLD3.gif)
![AASLD4.gif](../images/121615/121615-8/AASLD4.gif)
![AASLD5.gif](../images/121615/121615-8/AASLD5.gif)
![AASLD6.gif](../images/121615/121615-8/AASLD6.gif)
![AASLD7.gif](../images/121615/121615-8/AASLD7.gif)
![AASLD8.gif](../images/121615/121615-8/AASLD8.gif)
![AASLD9.gif](../images/121615/121615-8/AASLD9.gif)
![AASLD10.gif](../images/121615/121615-8/AASLD10.gif)
![AASLD11.gif](../images/121615/121615-8/AASLD11.gif)
![AASLD12.gif](../images/121615/121615-8/AASLD12.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|